Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache

Next Previous
Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary) ; Nonsteroidal anti-inflammatories; Paracetamol; Sumatriptan; Sumatriptan; Sumatriptan; Zolmitriptan; Zolmitriptan
  • Indications Cluster headache
  • Focus Registrational; Therapeutic Use
  • Acronyms CGAL
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 22 Apr 2021 Results (n=39 from CGAL, NCT02397473 who enrolled in CGAR, NCT02797951) assessing consistency of effect with galcanezumab for episodic cluster headache (ECH) across multiple cluster periods,presented at the 73rd Annual Meeting of the American Academy of Neurology
  • 25 Feb 2021 According to a Eli Lilly Canada Inc media release, Emgality (galcanezumab) is approved for use in Canada for the treatment of episodic cluster headache.
  • 11 Nov 2020 Results of a post hoc analysis assessing the treatment outcome in terms of median time-to-first occurrence of more than or equal to 50, more than or equal to 75, or 100% reduction from baseline in CH attack frequency, and impact on acute medication usepublished in the Headache

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top